Johnny Matheny is the first person to attach a mind-controlled prosthetic limb directly to his skeleton. After losing his arm to cancer in 2008, Johnny signed up for a number of experimental surgeries to prepare himself to use a DARPA-funded prosthetic prototype. The Modular Prosthetic Limb, developed by the Johns Hopkins Applied Physics Laboratory, allows Johnny to regain almost complete range of motion through the Bluetooth-controlled arm. (Video by Drew Beebe, Brandon Lisy) (Source: Bloomberg)
Category: biotech/medical
And the Singularity rolls ever on. And on.
“Cytokine converter” AND-gate synthetic-biology prosthesis used to treat psoriasis in mice. Top left: skin before; right: skin after. (credit: Lina Schukur et al./Science Translational Medicine)
An advanced “molecular prosthetic” — a cell with synthetic gene circuits that can be implanted into an organism to take over metabolic functions that the organism cannot perform itself — has been developed by ETH Zurich scientists.
Previous gene circuits typically monitored only whether one disease-causing molecule (called a cytokine) was present in their environment and if so, produced a single therapeutic cytokine as a response. The new “cytokine converter” synthetic circuit functions like an AND gate: It can detect two different cytokines simultaneously, and if (and only if) both are present, produces two different cytokines that can treat a disease.
In a landmark study, researchers have used gene editing system CRISPR-Cas9 to treat a model of Duchenne muscular dystrophy in mice
Proof of concept for future human treatment
While safety is still a concern, the use of gene editing methods to treat disease in adult patients isn’t controversial. Altering embryos is entirely different to treating an adult, predominantly as the implications are profound and an embryo obviously cannot give permission.
Moximed, a firm with offices in Hayward, California and Zurich, Switzerland, recently won the European CE Mark to introduce its Atlas Knee System. We just got hold of photos of the Atlas and more information on how it works. The device is a knee joint unloader designed to reduce the pressure applied to the joint and to push off the eventual need for a knee replacement. The device works like the shock absorbers in your car, but instead for the knee. It results in less damage to the cartilage within the knee, letting it last longer than it would naturally without the support of the Atlas.
The company hopes the device will allow patients to maintain an active lifestyle they’re used to while improving satisfaction, reducing repeat surgeries, and lowering pain.
From the announcement:
We may be fed a tale of ever expanding life expectancy, but while average lifespans may be rising maximum years are unchanged. If we want to keep extending the clock we need more than antibiotics and nutrition.
The easy work is done
While improving living standards and reducing infant mortality was not an easy job in itself, it extended years without fundamentally changing human biology. The incredible changes brought by the 20th century yielded longevity — but predominantly did so by lifting the majority closer to those luckier few. Even in the ancient world individuals seemingly lived over 80 years old; it was simply a rarer event to do so. You were significantly more likely to be felled by a disease beforehand, and many never reached such an advanced age as a result.
Researchers from the US will use the funds to create tech for those with spinal cord injuries and other debilitating conditions.
Patients needing surgery to reconstruct body parts such as noses and ears could soon have treatment using cartilage which has been grown in a lab.
The process involves growing someone’s cells in an incubator and then mixing them with a liquid which is 3D printed into the jelly-like shape needed.
It is then put back in an incubator to grow again until it is ready.
Three research groups, working independently of one another, reported in the journal Science on Thursday that they had used the Crispr-Cas9 technique to treat mice with a defective dystrophin gene. Each group loaded the DNA-cutting system onto a virus that infected the mice’s muscle cells, and excised from the gene a defective stretch of DNA known as an exon.
Without the defective exon, the muscle cells made a shortened dystrophin protein that was nonetheless functional, giving all of the mice more strength.
The teams were led by Charles A. Gersbach of Duke University, Eric N. Olson of the University of Texas Southwestern Medical Center and Amy J. Wagers of Harvard University.
Mosquito-borne disease affecting millions has had no approved vaccine until now
When female Aedes Aegypti mosquito sups on the blood of its human victims it too often deposits the virus that causes dengue, causing as many as 400 million infections per year worldwide. Severe forms of the painful, flu-like disease can be fatal, especially among children. And until recently there has been no truly effective prevention except avoiding getting bit. But the outlook against the disease is looking better.
During the past month Dengvaxia, developed by the French pharmaceutical company Sanofi, has been approved for use in three countries: Mexico and the Philippines approved the vaccine earlier this month. This week, the company also announced the drug has received the green light in Brazil, which has seen more than 1.4 million cases of the disease in 2015. Exactly when the inoculations will be deployed—and at what price—remains unclear as terms of the vaccine are being negotiated between the company and the countries.
It’s a new resin.
Researchers at Panasonic PCRFY −0.78% in Japan have developed a new kind of resin that has the potential to make personal health electronics leaner and comfier.
The stretchy tech, announced by the company on Dec. 28, can be used as a base for electronic materials. Its physical properties makes electronics easier to apply to skin or clothing—like a Band-Aid or a tattoo, rather than a watch or a strap.